Rare Disease Biotech Rallybio Targets $100M IPO

  • Rallybio Corporation RLYB ended the first quarter with nearly $128 million in the bank, and now it has filed to raise up to $100 million in its IPO to trade on NASDAQ under the symbol RLYB.
  • The news comes days after Rallybio established proof of concept for its lead program, RLYB211, in fetal and neonatal alloimmune thrombocytopenia (FNAIT). 
  • This rare disease causes a mother’s immune system to attack her fetus or newborn child’s platelets, the blood cells involved in clotting. 
  • RLYB211 is a polyclonal antibody treatment made by purifying antibodies from donated plasma and is designed to clear fetal platelets from the mother’s circulation, preventing the immune attack against them.
  • Data from the first cohort showed the candidate could “rapidly and completely clear” HPA-1a positive platelets from those without natural antigen defense. 
  • Six male participants saw their antigens cleared with a mean half-life of 0.32 hours, compared to the two on placebo with a mean half-life of 65.29 hours.
  • The IPO proceeds will fund the completion of the Phase 1/2 trial for RLYB211 and push a second FNAIT candidate, a monoclonal antibody dubbed RLYB212, into the clinic in Q1 of 2022.

Posted In: BriefsBiotechNewsHealth CareOfferingsIPOsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.